Literature DB >> 1605058

Inappropriate vasopressin secretion in severe alcohol withdrawal.

W Trabert1, D Caspari, P Bernhard, G Biro.   

Abstract

Forty-one male alcoholics suffering from alcohol withdrawal syndrome were investigated to assess the relationship between vasopressin (ADH), water homeostasis and alcohol withdrawal. During 10 d, we found a significant decrease in serum vasopressin, from 3.08 +/- 0.61 to 1.71 +/- 0.22 pg/nl. There were no concomitant changes in osmolality, so that a general dysregulatory state of vasopressin secretion during alcohol withdrawal cannot be assumed. Only patients with delirium tremens (8/41) had higher vasopressin levels despite lowered serum osmolalities. These findings support the hypothesis of an inappropriate rebound secretion of vasopressin in severe alcohol withdrawal. Furthermore, they may contribute to the pathogenesis of focal alcoholic brain damage, because rapid and/or profound changes in osmolality are suspected to cause circumscribed cerebral demyelinization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605058     DOI: 10.1111/j.1600-0447.1992.tb10322.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

Review 1.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 2.  Neuroinflammatory pathways in binge alcohol-induced neuronal degeneration: oxidative stress cascade involving aquaporin, brain edema, and phospholipase A2 activation.

Authors:  Michael A Collins; Edward J Neafsey
Journal:  Neurotox Res       Date:  2011-09-17       Impact factor: 3.911

Review 3.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

4.  A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Authors:  Megan L Ryan; Daniel E Falk; Joanne B Fertig; Beatrice Rendenbach-Mueller; David A Katz; Katherine A Tracy; Eric C Strain; Kelly E Dunn; Kyle Kampman; Elizabeth Mahoney; Domenic A Ciraulo; Laurie Sickles-Colaneri; Nassima Ait-Daoud; Bankole A Johnson; Janet Ransom; Charles Scott; George F Koob; Raye Z Litten
Journal:  Neuropsychopharmacology       Date:  2016-09-23       Impact factor: 7.853

5.  V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice.

Authors:  Yan Zhou; Marcelo Rubinstein; Malcolm J Low; Mary Jeanne Kreek
Journal:  Alcohol Clin Exp Res       Date:  2017-11-28       Impact factor: 3.455

6.  Syndrome of inappropriate antidiuretic hormone secretion associated with prolonged keterolac use.

Authors:  Sian Yik Lim; Ragesh Panikkath; Sharma Prabhakar
Journal:  Clin Nephrol Case Stud       Date:  2014-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.